tumor-initiating cells

September 26, 2018

AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial

News

The Phase 2 clinical trial evaluating AIVITA Biomedical’s cell-based immunotherapy for treating newly-diagnosed advanced ovarian cancer has dosed its first 10 patients. The study (NCT02033616) is looking to enroll 99 women at ... Read more

January 3, 2018

Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer

News

Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, ... Read more